

### **ORAL PRESENTATION**

**Open Access** 

# Infarct burden following multivessel PCI vs. infarct-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study

Kenneth Mangion<sup>1\*</sup>, David Carrick<sup>2</sup>, Alexander R Payne<sup>2</sup>, John D McClure<sup>1</sup>, Maureen Mason<sup>2</sup>, Mark Petrie<sup>2</sup>, Margaret McEntegart<sup>2</sup>, Hany Eteiba<sup>2</sup>, Keith G Oldroyd<sup>2</sup>, Colin Berry<sup>1</sup>

From 18th Annual SCMR Scientific Sessions Nice, France. 4-7 February 2015

#### **Background**

In the Preventive Angioplasty in Myocardial Infarction trial (PRAMI; ISRCTN73028481), immediate multivessel PCI (MV-PCI) of non-IRA (infarct related artery) lesions in patients with acute ST elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD) improved long term prognosis. We assessed infarct distribution and size in a pre-specified cardiac magnetic resonance (CMR) sub-study.

#### **Methods**

In this single centre prospective sub-study, PRAMI participants were invited to undergo 1.5 Tesla CMR 1 week and 1 year after primary PCI. The CMR scans were analysed using semi-automated software by a clinician blinded to treatment group assignment and clinical outcomes. The

presence and extent of infarction were assessed quantitatively with late gadolinium enhancement (LGE) imaging (Gadovist, 0.1 mmol/kg). The infarct was delineated as an area of myocardial enhancement (cm²) using a signal intensity threshold of >5SDs above a remote region, and expressed as a % of total LV mass. The incidence of new LGE in non-infarct related artery territories at baseline and 1 year were assessed. Data were analysed by an independent statistician.

#### Results

Of 465 randomised trial participants in 6 UK hospitals, 138 (30%) were enrolled in Glasgow. Of these 80 patients underwent CMR 1 week post primary PCI of whom 41 (51%) were in the multi-vessel PCI group and 39 (49%) were in the IRA-only group. At 1 year,

Table 1 Infarct size and distribution in non-infarct artery territory in the randomised PRAMI trial participants (n=80) in Glasgow

	Infarct-only PCI n = 39 (49%)	Multivessel PCI n=41 (51%)	р
	1 week post-MI		
Infarct size, % LV'	16.9 (14.0)	13.9 (12.1)	0.32
Infarct in non-IRA territory, n (%)	0 (0)	0 (0)	1.00
	1 year post-MI		
Infarct size, % LV	13.9 (10.1)	11.1 (11.2)	0.20
Change in infarct size from baseline, % LV mass*	-2.23 ( -9.97, 0.56)	-1.73 (-7.10, 0.94)	0.60
Infarct in non-IRA territory, n (%)	2 (5.1)	3 (7.3)	1.00

<sup>&#</sup>x27; mean (standard deviation)

<sup>1</sup>BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK

Full list of author information is available at the end of the article



<sup>\*</sup>median (interquartile range)

Mangion *et al. Journal of Cardiovascular Magnetic Resonance* 2015, **17**(Suppl 1):O9 http://www.jcmr-online.com/content/17/S1/O9

69 (86%) patients had a follow up CMR scan. Infarct size and distribution are described in Table 1.

#### **Conclusions**

Infarct size and distribution were similar in patients treated by MV-PCI or IRA-only PCI. MV-PCI is not associated with additional MI acutely which supports the safety of this procedure in line with the benefits observed with preventive PCI in PRAMI.

#### **Funding**

Golden Jubilee National Hospital; PRAMI was funded by Barts and the London Charity.

#### Authors' details

<sup>1</sup>BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. <sup>2</sup>Golden Jubilee National Hospital, Clydebank, UK.

Published: 3 February 2015

doi:10.1186/1532-429X-17-S1-O9

Cite this article as: Mangion *et al.*: Infarct burden following multivessel PCI vs. infarct-only PCI in patients with acute STEMI: the Glasgow PRAMI CMR sub-study. *Journal of Cardiovascular Magnetic Resonance* 2015 17(Suppl 1):O9.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

